![]() |
|
|
Vol. 29, Issue 7, 1068-1072, July 2001
Drug Metabolism and Pharmacokinetics Research Laboratories, New
Drug Development Division and Product Strategy Department, Sankyo Co.,
Ltd., Shinagawa-ku, Tokyo, Japan (M.I., K.K., W.T., T.I., T.K.); School
of Pharmaceutical Sciences, Kitasato University, Minato-ku, Tokyo,
Japan (K.I.); and Graduate School of Pharmaceutical Sciences,
University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.S.)
Taking into account the species and sex differences in drug
interactions based on the inhibition of cytochrome P450
(P450)-mediated drug metabolism, we examined whether the
interaction between simvastatin and itraconazole observed in humans
could also occur in rats, the most commonly used animal species for
pharmacokinetic studies. Itraconazole inhibited the in vitro metabolism
of simvastatin in female rat liver microsomes, but not in male rat
liver microsomes. Using anti-P450 antisera, the main P450 isozyme
responsible for the metabolism of simvastatin was identified as CYP3A
in female rats and CYP2C11 in male rats. Therefore, the sex difference
in the inhibition of simvastatin metabolism by itraconazole seems to be
caused by a difference in the P450 isozymes responsible for the
metabolism of simvastatin in male and female rats and the different
ability of itraconazole to inhibit CYP3A and CYP2C11. In addition, the
effect of itraconazole on the pharmacokinetics of simvastatin in rats
was also investigated. The area under the curve value of
simvastatin was increased approximately 1.6-fold by the concomitant use
of itraconazole (50 mg/kg) in female rats, whereas in male rats,
itraconazole had no effect. In conclusion, it was found that the
results obtained in male rats did not reflect the results in humans as
far as the inhibition of simvastatin metabolism by itraconazole was
concerned. The P450 isozymes involved in the metabolism of drugs should
be taken into consideration when rats are used as a model animal for
humans in the investigation of drug interactions.
This article has been cited by other articles:
![]() |
A. Ogasawara, I. Negishi, K. Kozakai, and T. Kume In Vivo Evaluation of Drug-Drug Interaction via Mechanism-Based Inhibition by Macrolide Antibiotics in Cynomolgus Monkeys Drug Metab. Dispos., November 1, 2009; 37(11): 2127 - 2136. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ogasawara, M. Utoh, K. Nii, A. Ueda, T. Yoshikawa, T. Kume, and K. Fukuzaki Effect of Oral Ketoconazole on Oral and Intravenous Pharmacokinetics of Simvastatin and Its Acid in Cynomolgus Monkeys Drug Metab. Dispos., January 1, 2009; 37(1): 122 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Laudi, S. Trump, V. Schmitz, J. West, I. F. McMurtry, H. Mutlak, U. Christians, J. Weimann, U. Kaisers, and W. Steudel Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L630 - L638. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ishigami, W. Takasaki, T. Ikeda, T. Komai, K. Ito, and Y. Sugiyama Sex Difference in Inhibition of In Vitro Mexazolam Metabolism by Various 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors in Rat Liver Microsomes Drug Metab. Dispos., August 1, 2002; 30(8): 904 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Subramanian, X. Fang, and T. Prueksaritanont Structural Characterization of in Vivo Rat Glutathione Adducts and a Hydroxylated Metabolite of Simvastatin Hydroxy Acid Drug Metab. Dispos., March 1, 2002; 30(3): 225 - 230. [Abstract] [Full Text] [PDF] |
||||